Highly Characterized Patient- Derived Xenograft Collections for Preclinical Efficacy Studies

Transcription

1 HORIZON DISCOVERY Highly Characterized Patient- Derived Xenograft Collections for Preclinical Efficacy Studies Jochen Hartner, Field Application Leader

2 About Horizon Discovery Powering Genomic Research and Translational Medicine, from Sequence to Treatment Horizon s mission is to be a fully integrated life science company that provides enabling products, services and research programs to clients engaged at every stage of the healthcare continuum from sequence to treatment 2

3 3

4 In Vivo Portfolio Overview SAGESpeed Genetically Engineered Animal Models More than 300 gene-edited animal models generated Technology leaders (first KO rat, first KI rat, first cko rat, first KO rabbit by gene editing) Strong IP position on the use of CRISPR-Cas9 and ZFN technology Wide spectrum of genetic modifications, including KO, cko, HUM, KI, cki, TTG, cttg, random TG Experience with gene editing in rats (multiple strains), mice (multiple strains), and rabbits Delivery of heterozygous or homozygous live animals or cryopreserved embryos Fully documented project reports and comprehensive project management Patient Derived Xenograft Models Efficacy study services (both in vivo and ex vivo) Pharmacokinetic (PK)/Pharmacodynamic (PD) analysis Tolerability studies Establish in vivo growth curves Provide histological processing of tissue Tumor sequencing Transgenic Support Services Custom breeding and colony expansion Cryopreservation and recovery Blood, serum, plasma and tissue sampling Protein/mRNA expression analysis and off-target analysis In vivo assay services 4

5 In Vivo Operational Overview Horizon utilizes state-of-the-art barrier facilities and biobubble Clean Rooms for housing all PDX mice Individually ventilated rack systems are used Use of the TumorImager system enables accurate and efficient measurement of subcutaneous tumors Expert technicians follow carefully written and approved SOPs AALAS training programs provide our staff with ongoing professional development in animal health, husbandry, and genetics, 82% of animal technicians carry an AALAS certification Horizon s animal vivarium is AAALAC accredited and holds a PHS assurance number with OLAW for work with all government funded labs 5

6 In Vivo Models of Human Cancer Genetically Engineered Models Oncogene-expressing / tumor suppressor-deficient mice CDX Models Human cancer cell line transplanted into immunocompromised mice PDX Models Human primary tumor transplanted into immunodeficient mice PDX Models (Humanized Immune System) Human primary tumor transplanted into immunodeficient mice reconstituted with a (partial) human immune system Syngeneic Models Mouse primary tumor transplanted into immunocompetent mice 6

7 Horizon Discovery s Current PDX Offerings Washington University Human In Mouse (WHIM) Breast Cancer PDX Model Collection Vials of cells available In vivo propagation Non-viable analysis materials (snap-frozen, FFPE) Efficacy studies 2D versus 3D ex vivo culturing Wistar Melanoma (WM) PDX Model Collection Vials of cells available In vivo propagation Efficacy studies 7

8 The Washington University St. Louis Breast Cancer PDX Model Collection Li et al. Cell Reports (2013) 4: Huang et al. Nat. Comms. (2017) 8:

9 Horizon Discovery s Breast Cancer PDX Offering Models are published World-class collection of 20+ models: 8 ER+, 2 HER2+ and 12 triple-negative breast cancer (TNBC) models Highly characterized, genetic fidelity confirmed: WGS of originating tumor, early, and late passages (13 models) Comprehensive patient history RNAseq profile Fulvestrant (SERD) resistance Estradiol responsiveness Quantitative proteomics profile: PG signatures of PDXs resemble findings from breast cancer patients PDX tumors recapitulated proteomic diversity of human breast cancers Also identified overexpressed proteomic events not evident at the genomic level in both PDX and human samples Available: Suspended PDX cells Mice bearing tumors In-house in vivo and ex vivo efficacy studies 9

10 WHIM Breast Cancer Model Online Database 10

11 Propagation of a WHIM PDX Model in NSG Mice WHIM20 PAM50: Lumenal A Met: Skin +/-/+ Estrad. Indep. Tamoxifen resistance mutation in ESR1 (Y537S) 11

12 Human Stroma is Rapidly Replaced by Mouse Stroma in PDX Models In PDX models, tumor architecture is preserved, albeit with mouse stromal components Li et al. Cell Reports (2013) 4: WHIM6 hybridized with both human and mouse specific centromere probes 12

13 Horizon Discovery s Pipeline for PDX Efficacy Testing Order mice 5 Days acclimation 1.5 Mio. cells Inoculate mice mm 3 Mice recruited in study and randomized Mice euthanized mm 3 Mice treated weighed, imaged Products: Tumor material Growth curves PK/PD Genetics Histology 13

14 M e a n T u m o r V o l u m e ( m m 3 ) Efficacy in Three PDX Studies Completed by Horizon Discovery Using the WHIM20 and WHIM5 Models 10 animals/cohort Data expressed as Mean ± S.E.M. WHIM20 WHIM5 M e a n G r o w t h o f W H I M 5 P D X T u m o r s i n A t h y m i c N u d e M i c e control drug V e h i c l e C o m p o u n d h i g h d o s e C o m p o u n d l o w d o s e C o m p o u n d D a y s P o s t D o s e PAM50: Lumenal A Met: Skin +/+/- Estradiol Indep. PAM50: Basal Met: Brain -/-/- p53 S166S ins. Tamoxifen resistance mutation in ESR1 (Y537S) 14

15 M e a n T u m o r V o l u m e ( m m 3 ) Efficacy of Cyclophosphamide and Doxorubicin in Athymic Nude Mice Bearing WHIM6 TNBC Tumors WHIM6 W H I M 6 E f f i c a c y D a t a U n t r e a t e d C o n t r o l S a l i n e V e h i c l e C y c l o p h o s p h a m i d e m p k i p q 7 d D o x o r u b i c i n 2 m p k i p q 7 d C o m b i n a t i o n 10 animals/cohort Data expressed as Mean ± S.E.M. d o s e d o s e d o s e D a y s a f t e r 1 s t D o s e PAM50: Basal Primary: Breast -/-/- 15

16 3D Spheroid Formation by WHIM Cells is Superior to 2D Culture ER/PR/HER2 -/-/- +/+/- +/+/- -/-/- 16

17 3D Spheroids Are Highly Efficient in Inducing Tumor Formation (1.5M) (1.0M) (0.1M) 10 animals/cohort Data expressed as Mean ± S.E.M. 17

18 The Wistar Institute Melanoma PDX Model Collection 18

19 The Wistar Institute Melanoma PDX Model Collection Horizon has access to 150 out of 465 PDXs Molecularly characterized (Targeted NGS, RPPA) Robust tumor formation Low passage numbers 19

20 PDX Models Established from Targeted Therapy Relapsed Melanoma Patients Post-therapy PDX models # BRAF inhibitors 39 BRAF/MEK inhibitors 31 Immune checkpoint inhibitors 100 TT/IT combination 10 Patient w/pd BRAFi BRAFi MEKi BRAFi diet BRAFi/MEKi diet Clemens Krepler, The Wistar Institute 20

21 Propagation of Wistar Melanoma PDX Models in NSG Mice WM3983 (P3) WM4237 (P3) WM (P3) PDX ID Subtype Passage available Age at Bx Primary Gender Biopsy site tumor type Stage at Bx WM3983 BRAF-R 4 83 F SQ SSM IV WM4237 BRAF 4 28 F BRAIN WM BRAF-R 4 77 M MET Unknown Primary MULTIPLE PRIMARIES Targeted therapy prior to Bx vemurafenib, isolated progression, PFS 29.6 weeks, OS 86 weeks Immune therapy prior to Bx None BRAF hotspot/ RAS/ NF1/ KIT/ WT BRAFV600K NRASQ61K IV None Ipilimumab, PD BRAFV600E IV vemurafenib, mixed response, PFS 46.7 weeks, OS 58.7 weeks None BRAFV600E 21

22 Cell Number Dependent Growth of Wistar Melanoma 4237 Tumors in Athymic Nude Mice WM4237 (0.5M cells / mouse WM4237 (1.0M cells / mouse 10 animals/cohort Data expressed as Mean ± S.E.M. 22

23 Summary and Outlook Breast Cancer PDX Model Collection (WHIMs) Wistar Melanoma PDX Model Collection X-MAN Isogenic and CCLE Derived Cell Lines for Xenograft Studies (CDX) Expand PDX platform with clinically relevant models Evaluating options to support immuno-oncology investigators 23

24 Acknowledgements Horizon Discovery, St. Louis, USA Michele Melton Athena Bast Stacy Deeds Aaron McCoy Mohit Sachdeva Chris Eden Jermaine Gardner Kevin Forbes Washington University, St. Louis, USA Shunqiang Li Tina Primeau The Wistar Institute, Philadelphia, USA Clemens Krepler Katrin Sproesser 24